ReviewCureus2025
Distribution of Immunohistochemical Subtypes of Breast Cancer in Nigeria: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the most common cancer seen in women worldwide. Great strides have been made in its management even in low- and medium-income countries such as Nigeria. Immunohistochemistry is essential in planning treatment, with the increasing availability of hormonal and other targeted therapies. This systematic review aims to review the immunohistochemical subtypes of breast cancer seen in Nigeria. A literature search was done on PubMed, Google Scholar, and African Journal Online databases for publications on the immunohistochemical subtypes of breast cancer in Nigeria using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Articles were selected on the basis of their relevance to immunohistochemistry of breast cancer in Nigeria. A total of 17 studies published between 2005 and 2024, comprising 3,017 patients, met the inclusion criteria. Geographically, most were from the South West region (n=8), followed by South South (n=4), North Central (n=3), and one each from the South East and North West. Sixteen studies, with a total of 2,846 subjects, reported hormone receptor status. Estrogen receptor-positive (ER+) rates ranged from 10.9% to 65.1%, progesterone receptor-positive (PR+) rates from 12.5% to 70.7%, human epidermal growth factor receptor 2-positive (HER2+) rates from 5.2% to 62.5%, and triple-negative breast cancer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.